InMed Pharmaceuticals (INM) Gross Profit (2022 - 2025)
Historic Gross Profit for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $403159.0.
- InMed Pharmaceuticals' Gross Profit fell 1829.18% to $403159.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 274.92%. This contributed to the annual value of $1.7 million for FY2025, which is 5501.55% up from last year.
- According to the latest figures from Q3 2025, InMed Pharmaceuticals' Gross Profit is $403159.0, which was down 1829.18% from $576654.0 recorded in Q2 2025.
- InMed Pharmaceuticals' 5-year Gross Profit high stood at $1.6 million for Q2 2023, and its period low was -$491018.0 during Q3 2022.
- For the 5-year period, InMed Pharmaceuticals' Gross Profit averaged around $322327.5, with its median value being $269586.0 (2022).
- Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Gross Profit was 222281.8% (2024), while the steepest drop was 7032.11% (2024).
- Quarter analysis of 5 years shows InMed Pharmaceuticals' Gross Profit stood at $111555.0 in 2021, then rose by 17.58% to $131163.0 in 2022, then soared by 147.13% to $324142.0 in 2023, then skyrocketed by 42.19% to $460894.0 in 2024, then fell by 12.53% to $403159.0 in 2025.
- Its Gross Profit was $403159.0 in Q3 2025, compared to $576654.0 in Q2 2025 and $175625.0 in Q1 2025.